Medical Xpress

FEBRUARY 21, 2023

Minority ethnicities and regions derive at least as much cardiovascular benefit from lipid-lowering therapies as majority groups despite being underrepresented in clinical trials, according to a study published today in the European Journal of Preventive Cardiology.

Cardiology 72

Cardiology Clinical Trials Clinical Trials Drugs 72

Rethinking Clinical Trials

JUNE 7, 2023

The trial was designed to randomize 1,000 patients who had an On-X aortic valve replacement at least 3 months prior to randomization with either a standard dose of Apixaban (5mg) or continued warfarin (the standard of care). The drugs were administered open label and all patients were given a low dose of aspirin.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Cardiology 100

XTalks

DECEMBER 2, 2024

The US Food and Drug Administration (FDA) has approved AOP Health’s landiolol injection, marketed as Rapiblyk, for the treatment of atrial fibrillation (Afib) and atrial flutter in critical care settings. The approval is grounded in data from five randomized, double-blind, placebo-controlled trials involving 317 adults.

Trials 104

Trials Marketing FDA Approval Life Science 104

pharmaphorum

MARCH 9, 2021

Novartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless a disappointing feeling when things don’t work out. The post Novartis’ canakinumab falls short in phase 3 lung cancer trial appeared first on.

Trials 59

Trials Cardiology Branding Sales 59

Scienmag

NOVEMBER 16, 2020

SCORED trial of patients with diabetes and chronic kidney disease is first trial of an SGLT2 inhibitor to show benefit across the full range of albuminuria; SOLOIST shows an SGLT2 inhibitor is safe to start in patients hospitalized with heart failure Boston, MA — Less than a decade ago, the Food and Drug Administration approved […].

Trials 65

Trials Drugs Clinical Trials Clinical Trials 65

XTalks

NOVEMBER 21, 2024

The US Food and Drug Administration (FDA) has granted Breakthrough Device clearance to Ultromics’ EchoGo Amyloidosis device through its Total Product Lifecycle Advisory Program (TAP). One such study, the PREVAMIC trial conducted in Spain , found that cardiac amyloidosis was present in 20.1

Production 105

Production Protein Life Science Trials 105

Medical Xpress

MARCH 16, 2023

Lifestyle changes and blood pressure-reducing drugs are the mainstays of therapy for hypertension, but despite widespread availability of these approaches, many patients with hypertension are not adequately treated. Hypertension remains poorly controlled worldwide and is becoming more common.

Trials 88

Trials Drugs Cardiology 88

XTalks

APRIL 7, 2022

Abbott Laboratories announced on Monday that the US Food and Drug Administration (FDA) approved its Aveir™ single-chamber (VR) leadless pacemaker system. XTALKS WEBINAR: Cardiac Safety Solutions in Decentralized Clinical Trials (DCT). Live and On-Demand: Tuesday, May 24, 2022, at 1pm EDT (10am PDT).

FDA Approval 105

FDA Approval Clinical Trials Clinical Trials Cardiology 105

Scienmag

OCTOBER 19, 2020

Randomized clinical trial finds no mortality risk or benefit associated with drug-coated devices in the treatment of peripheral artery disease NEW YORK – October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) (..)

Trials 51

Trials Clinical Trials Clinical Trials Drugs 51

Medical Xpress

DECEMBER 6, 2024

The HAVEN 7 trial showed that emicizumab is both safe and effective in protecting infants from brain bleeds, although concerns were raised about the affordability of this drug. Emicizumab (Hemlibra) was approved by the FDA in 2018 to prevent and reduce bleeding for patients who suffer from hemophilia A.

Genetics 66

Genetics Drugs Trials Cardiology 66

XTalks

JANUARY 3, 2025

Ionis Pharmaceuticals recently announced that its drug, Tryngolza (olezarsen), has been approved as an adjunct to diet for the reduction of triglyceride levels in FCS patients, who have long faced a condition with no existing pharmacological solutions. In the Balance study, patients who received the drug showed a 42.5

FDA Approval 59

FDA Approval Drugs Clinical Trials Clinical Trials 59

Scienmag

NOVEMBER 13, 2020

Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai.

Clinical Trials 61

Clinical Trials Clinical Trials Drugs Medicine 61

pharmaphorum

JUNE 17, 2022

The UK-based but US-listed biotech licensed rights to AZ’s orally-active neutrophil elastase inhibitor alvelestat for the rare disease alpha-1 antitrypsin deficiency (AATD) five years ago, and has since advanced the project into a phase 2 trial which is due to read out in the second half of this year.

Licensing 81

Licensing Licensing Cardiology Antibody 81

The Pharma Data

AUGUST 30, 2021

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published today in the Journal of the American College of Cardiology (JACC).

Drugs 52

Drugs Cardiology Clinical Trials Clinical Trials 52

pharmaphorum

MAY 18, 2021

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. Data were announced at the virtual American College of Cardiology annual conference and published simultaneously in The Lancet.

Drugs 52

Drugs Cardiology Trials Clinical Trials 52

pharmaphorum

AUGUST 13, 2020

The cholesterol-lowering drug has been classed as a breakthrough therapy for homozygous familial hypercholesterolaemia (HoFH) by the FDA, which is due to deliver a decision on the marketing application by 11 February after a truncated six-month review. Analysts put peak US sales in the region of $200 million to $400 million.

Drugs 52

Drugs Antibody Sales Cardiology 52

Velocity Clinical Research

NOVEMBER 21, 2023

Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market. She’s been involved in several trials that have made a difference for patients, including Entresto, a drug that’s been “a big step forward for heart failure patients,” she says.

Medicine 59

Medicine Cardiology Clinical Research Clinical Trials 59

Scienmag

NOVEMBER 16, 2020

ET, Monday, November 16, 2020, Cleveland: Cleveland Clinic researchers leading a global clinical trial have found that rilonacept, an FDA approved drug for other inflammatory diseases, resolved acute pericarditis episodes and reduced risk of […].

Trials 41

Trials FDA Approval Clinical Trials Clinical Trials 41

pharmaphorum

JUNE 1, 2021

The Danish drugmaker has acquired exclusive rights outside Japan to Heartseed’s HS-001 therapy based on heart muscle cells (cardiomyocytes) derived from human stem cells, and is due to start the phase 1/2 LAPiS trial in Japan later this year. An interim look at the results is due later this month.

Trials 138

Trials Development Licensing Licensing 138

XTalks

JULY 7, 2023

a Canadian biopharmaceutical firm specializing in cardiovascular therapies, recently reported positive results from a Phase III clinical trial of its leading candidate, etripamil nasal spray, for the treatment of paroxysmal supraventricular tachycardia (PSVT). Milestone Pharmaceuticals Inc., It is then efficiently metabolized by the body.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Drugs 98

pharmaphorum

OCTOBER 8, 2020

UK-based RHYTHM AI is to go ahead with a larger clinical trial of its artificial intelligence (AI)-driven system, which could be used as a treatment for atrial fibrillation without the need for medication. The post RHYTHM AI cleared for large trial of atrial fibrillation mapping tool appeared first on. months follow up.

Trials 52

Trials Clinical Trials Clinical Trials Clinical Development 52

The Pharma Data

AUGUST 30, 2021

Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments.

Trials 52

Trials Genetics Cardiology Medicine 52

XTalks

JUNE 11, 2024

The US Food and Drug Administration (FDA) recently approved Boston Scientific’s Agent drug-coated balloon (DCB) for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease (CAD). Key Features of the Agent Drug-Coated Balloon One of the standout features of the Agent DCB is its TransPax Coating Technology.

Drugs 52

Drugs Drug Delivery Cardiology Marketing 52

Medical Xpress

DECEMBER 5, 2022

Some immunomodulators—drugs that decrease inflammation—have been shown to reduce CV risk in the general population. People with rheumatoid arthritis are at increased risk of cardiovascular (CV) disease, with studies indicating an approximate 50 percent increase in risk of CV events such as heart attack and stroke.

Trials 65

Trials Drugs Cardiology 65

Scienmag

OCTOBER 21, 2020

Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.

Drugs 73

Drugs Research Clinical Trials Clinical Trials 73

pharmaphorum

FEBRUARY 10, 2022

The FDA has granted fast-track status to Bayer’s oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs. All three studies are looking at the drug on its own and in combination with anti-platelet therapies like aspirin and clopidogrel.

Drugs 98

Drugs Sales Antibody Regulation 98

Velocity Clinical Research

DECEMBER 6, 2023

In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. About Velocity Clinical Research Velocity is the leading integrated site organization for clinical trials. and Europe. and Europe.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

The Pharma Data

MARCH 22, 2022

New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease. senior vice president, head of cardiovascular development and global drug development at Bristol Myers Squibb. “We

Clinical Trials 52

Clinical Trials Clinical Trials Cardiology Trials 52

Delveinsight

AUGUST 4, 2020

MorphoSys in-licensed Monjuvi, which is a humanized Fc-engineered monoclonal antibody against CD19 – the same protein which CAR-T cell therapies target and is in abundance in cancerous B cells, from Xencor in 2010 and is under evaluation in B-cell malignancies in several ongoing combination trials.

Cardiology 55

Cardiology Antibody FDA Approval Trials 55

Delveinsight

JULY 22, 2021

This early-stage trial is set to enroll ten patients across the US and Canada, with its primary aim to evaluate the safety and tolerability of DA01 cell transplantation at one year post-transplant. It looks to carry on with a new class of oral, once-daily, small molecule drugs called Controlled Metabolic Accelerators (CMAs).

Cardiology 98

Cardiology Development Engineer Clinical Trials 98

pharmaphorum

OCTOBER 24, 2022

Bristol-Myers Squibb is going after a second indication for its first-to-market cardiac myosin inhibitor Camzyos, a drug tipped to be a future blockbuster and the top prospect in the company’s growing cardiovascular pipeline. In the trial, Camzyos or placebo was added to the highest tolerated dose of standard therapy.

Drugs 40

Drugs Sales Pharmacy Trials 40

The Pharma Data

JUNE 28, 2021

The approval is based on the results of the pivotal Phase III VICTORIA trial, published in The New England Journal of Medicine (NEJM) in March 2020. Bayer is proud of the approval of vericiguat in Japan and the contribution it has shown in clinical trials.”. Verquvo (vericiguat) 2.5 Verquvo (vericiguat) was approved by the U.S.

Cardiology 52

Cardiology Production Development Medicine 52

The Pharma Data

NOVEMBER 19, 2020

But after giving the patients an unmarked eight-month supply of statins and dummy pills (four bottles of each), the investigators found that 90% of the symptoms reported when taking the real drug endured, even when patients were taking a dummy (placebo) pill. The study received no drug industry funding.

Cardiology 52

Cardiology Drugs Research Containment 52

The Pharma Data

FEBRUARY 21, 2022

We are taking bold steps into the future of drug development, investing strongly in areas at the forefront of the biomedical and technological revolution. Strong pipeline with robust late-stage development program and broad potential across indications.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

APRIL 28, 2022

In the trial, the safety profile of Ultomiris was comparable to placebo and consistent with that observed in Phase III trials of Ultomiris in paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS). The trial enrolled 175 patients across North America, Europe, Asia-Pacific and Japan.

Antibody 52

Antibody Trials Medicine Cardiology 52

Trialfacts

APRIL 2, 2024

Upon entering the treatment phase, there will be a 16-week ramp-up period during which the amount of study drug is gradually increased to aid the body in acclimating to the treatment. CORE Research Group CORE Research Group is owned and run by a consultant cardiologist and has successfully run clinical trials for almost 30 years.

Research 52

Research Cardiology Clinical Trials Clinical Trials 52

Delveinsight

AUGUST 3, 2021

The Late-Breaking Trial Data at TVT Prove Sustained Safety and Performance of WATCHMAN FLX Left Atrial Appendage Closure Device. According to analyst views, interventional cardiology sales grew at around 7% in the first quarter of 2021 versus 2020 with structural heart franchise WATCHMAN, ACURATE neo2, and SENTINEL.

FDA Approval 98

FDA Approval Marketing Cardiology Production 98